Paper Details

  1. Home
  2. Paper Details

Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.

Author: BertoliniFederica, BonizzoniErminio, BriaEmilio, CarnioSimona, CassanoAlessandra, CavannaLuigi, CelioLuigi, ChiariRita, CogoniAlessio Aligi, CollovàElena, CortinovisDiego, De PlacidoSabino, GernoneAngela, LetiziaAntonietta, MartelliOlga, MisinoAndrea, PetrelliFausto, PilottoSara, PiscontiSalvatore, VittimbergaIsabella, ZanelliFrancesca

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated a new approach to reduce the overall amount of dexamethasone (DEX) used in patients receiving chemotherapy with cisplatin. The study compared the effectiveness of giving DEX on the first day of treatment, with or without low-dose DEX on the following days, to the standard practice of giving DEX for four days. The study found that the shorter DEX regimen was non-inferior to the standard regimen, suggesting that this new approach could potentially reduce the risk of side effects associated with DEX exposure.
Paper Details　
Original Abstract of the Article :
To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin-based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or without low-dose DEX on days 2 and 3, combined with an oral fixed-dose combination of netupitant and palonosetron (NEPA), compared with t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488764/

データ提供：米国国立医学図書館（NLM）

Reducing Dexamethasone Exposure in Cisplatin-Based Chemotherapy

The field of oncology is always seeking to minimize the side effects of chemotherapy, aiming to improve the quality of life for cancer patients. This study explores the potential of reducing dexamethasone (DEX) exposure in patients receiving cisplatin-based chemotherapy. The researchers conducted a randomized noninferiority study, comparing different regimens of DEX with an oral fixed-dose combination of netupitant and palonosetron (NEPA) for the prevention of emesis. Their findings demonstrate that reducing DEX exposure while incorporating NEPA is a noninferior strategy for preventing emesis, potentially leading to fewer side effects and improved patient comfort. This study highlights the importance of optimizing chemotherapy regimens to minimize adverse effects and enhance the overall patient experience.

A More Tolerable Chemotherapy Experience

The study's findings suggest that reducing DEX exposure while incorporating NEPA is a viable strategy for preventing emesis in patients receiving cisplatin-based chemotherapy. This approach could potentially lead to fewer side effects, such as weight gain and mood changes, associated with prolonged DEX use. The study's results provide valuable insights into optimizing chemotherapy regimens to improve patient comfort and tolerability. This research is a valuable contribution to the ongoing efforts to enhance the quality of life for cancer patients undergoing treatment.

Optimizing Cancer Treatment: A Balancing Act

This study emphasizes the importance of finding a balance between achieving therapeutic efficacy and minimizing adverse effects in cancer treatment. The researchers demonstrate that reducing DEX exposure while incorporating NEPA can effectively prevent emesis without compromising treatment effectiveness. The study highlights the need for a personalized approach to chemotherapy, carefully considering individual patient needs and tailoring treatment plans to optimize outcomes. This research underscores the importance of continuous innovation and the pursuit of improved cancer treatment strategies.

Dr.Camel's Conclusion

This study is like a camel navigating a desert, seeking the most comfortable and efficient route to reach its destination. The researchers carefully explore different treatment options, finding a balance between efficacy and minimizing side effects. This research is a valuable step towards improving the overall experience for cancer patients undergoing treatment, ensuring a smoother and more comfortable journey through the challenges of cancer care.

Date :
  1. Date Completed 2021-10-25
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34101934

DOI: Digital Object Identifier

PMC8488764

Related Literature

Article Analysis
・Effects of netupitant and palonosetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.